Chicago, IL – March 10, 2025 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: https://www.zacks.com/stock/news/2427441/3-stocks-breaking-out-right-now)
Welcome to Episode #436 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life.
This week, Tracey is going solo to look at stocks that are bucking the bearish trend on Wall Street. Instead, these three stocks are touching new all-time highs.
They aren't technology stocks, although one is in the rare group of trillion-dollar market cap companies along with the Magnificent 7 stocks.
These are mostly "old economy" type companies in paints, railroads, energy, insurance, and big cap pharmaceuticals.
1. Berkshire Hathaway (BRK.B)
Berkshire Hathaway is involved in just about every type of business you can think of. It also has a large equity portfolio which owns some Mag 7 stocks like Amazon and Apple.
Investors are hiding out in Berkshire Hathaway in 2025. Shares of Berkshire Hathaway are up 9.3% year-to-date and are in the green over the last month. The stock has busted out to new all-time highs this year.
Berkshire Hathaway is not a cheap stock. It has a forward price-to-earnings (P/E) ratio of 24.5. A P/E under 15 is often considered a "value" stock.
Even Warren Buffett is staying out of it as Berkshire Hathaway did not repurchase any shares with its cash last quarter.
Is Berkshire Hathaway the ultimate defensive play in 2025?
2. Aon plc AON
Aon is a global professional services firm with commercial risk, reinsurance, and wealth solutions, among others. Earnings are expected to rise 10.3% in 2025.
Shares of Aon have been hitting new all-time highs the past 2 weeks even as the tariffs have roiled the markets. Aon is up 11.8% year-to-date.
Aon is trading with a forward P/E of 23.5. It also pays a dividend, yielding 0.7%.
Should Aon be on your short list for 2025?
3. AbbVie Inc. ABBV
AbbVie is a big cap pharmaceutical company which had one of the blockbuster drugs, Humira, over the last decade. But Humira recently went off patent. AbbVie has been trying to replace the revenue. Has it succeeded?
AbbVie has Skyrizi, Rinvoq, and Botox in its product line up now. Earnings are expected to rise 21.6% in 2025.
Shares of AbbVie were hitting new highs this week while the tariffs were rocking the stock market. AbbVie is up 18% year-to-date. Yet it's still attractively priced. AbbVie has a forward P/E of 17.2.
AbbVie also pays a dividend, yielding 3.1%.
Should investors hide out in AbbVie in 2025?
What Else Do You Need to Know About Stocks Breaking Out?
Tune into this week's podcast to find out.
[In full disclosure, Tracey owns shares of ABBV in her personal portfolio and in Zacks Value Investor and shares of AON in the Insider Trader portfolio.]
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report
Aon plc (AON) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.